Dear Editor, we thank Wang et al. for their suggestions on potential matters to optimize the Caravaggio score [1]. The recently published Caravaggio score was aimed to stratify the risk of recurrence during anticoagulant therapy in patients with cancer associated venous thromboembolism (CAT) [2]. Main findings showed that the combination of 6 clinical items identify more than one-fifth of CAT patients as those with a low risk for recurrence during the first 6 months of anticoagulant therapy (2.5 % in the Caravaggio derivation cohort and 1.7 % in the TESEO validation cohort), with a negative predictive value of 98 % (in both cohorts) [2].
